Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meg Doherty

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Journal of the International AIDS Society|July 11, 2017
Clinical and public health implications of acute and early HIV detection and treatment: a scoping reviewSarah E Rutstein, Jintanat Ananworanich, Sarah Fidler, et al.
Nature Communications|July 2, 2025
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
Eclinicalmedicine|December 9, 2020
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysisSteve Kanters, Marco Vitoria, Michael Zoratti, et al.
The Lancet. HIV|August 9, 2017
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysisSteve Kanters, Maria Eugenia Socias, Nicholas I Paton, et al.
Nature Communications|April 17, 2026
Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
The Lancet. HIV|October 2, 2015
Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysisNathan Ford, Zara Shubber, Graeme Meintjes, et al.
The Lancet. Infectious Diseases|December 4, 2014
The future role of CD4 cell count for monitoring antiretroviral therapyNathan Ford, Graeme Meintjes, Anton Pozniak, et al.
The Journal of Infectious Diseases|November 17, 2020
Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysisSilvia Bertagnolio, Lucas Hermans, Michael R Jordan, et al.
The Lancet. HIV|September 10, 2019
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 listMartina Penazzato, Claire L Townsend, Natella Rakhmanina, et al.
Open Forum Infectious Diseases|January 14, 2022
Cost-effectiveness of Routine Provider-Initiated Testing and Counseling for Children With Undiagnosed HIV in South AfricaTijana Stanic, Nicole McCann, Martina Penazzato, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Journal of the International AIDS Society|July 11, 2017
Clinical and public health implications of acute and early HIV detection and treatment: a scoping reviewSarah E Rutstein, Jintanat Ananworanich, Sarah Fidler, et al.
Nature Communications|July 2, 2025
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
Eclinicalmedicine|December 9, 2020
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysisSteve Kanters, Marco Vitoria, Michael Zoratti, et al.
The Lancet. HIV|August 9, 2017
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysisSteve Kanters, Maria Eugenia Socias, Nicholas I Paton, et al.
Nature Communications|April 17, 2026
Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
The Lancet. HIV|October 2, 2015
Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysisNathan Ford, Zara Shubber, Graeme Meintjes, et al.
The Lancet. Infectious Diseases|December 4, 2014
The future role of CD4 cell count for monitoring antiretroviral therapyNathan Ford, Graeme Meintjes, Anton Pozniak, et al.
The Journal of Infectious Diseases|November 17, 2020
Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysisSilvia Bertagnolio, Lucas Hermans, Michael R Jordan, et al.
The Lancet. HIV|September 10, 2019
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 listMartina Penazzato, Claire L Townsend, Natella Rakhmanina, et al.
Open Forum Infectious Diseases|January 14, 2022
Cost-effectiveness of Routine Provider-Initiated Testing and Counseling for Children With Undiagnosed HIV in South AfricaTijana Stanic, Nicole McCann, Martina Penazzato, et al.
Pageof 12